Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem
- Written by PR Newswire
![]() |
Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026
SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem®/UE2343 once-a-day small molecule in accordance...